NCT04051944

A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to assess long-term safety and tolerability of weekly doses of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

Conditions

• Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Interventions

Type	Name	Description
DRUG	Rozanolixizumab	Subjects will receive rozanolixizumab in a specified sequence during the treatment period.

Timeline

• Start date: 2019-08-21
• Primary completion: 2021-11-10
• Completion: 2021-11-10
• First posted: 2019-08-09
• Last updated: 2022-11-03
• Results posted: 2022-11-03

Locations

14 sites across 8 countries: United States, Belgium, Denmark, France, Germany, Netherlands, Spain, United Kingdom

Regulatory

• FDA-regulated drug study